LPAR2 and breast carcinoma: Lysophosphatidic acid-3 is less abundant than LPA1 or LPA2 in breast cancer cells (Chen et al, 2007) and did not seem to be altered in patients with metastatic breast cancer (Kitayama et al, 2004).